Atlas Trials

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Clinical trial NCT00636740 · COMPLETED

Trial details

NCT number
NCT00636740
Sponsor
Merrion Pharmaceuticals, LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hormone-Refractory Prostate Cancer
Start date
2008-02-01
Primary completion
2009-02-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.